Patents by Inventor Martin Bertschinger

Martin Bertschinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic Cells
    Publication number: 20200172634
    Abstract: The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile.
    Type: Application
    Filed: July 16, 2019
    Publication date: June 4, 2020
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Christel AEBISCHER-GUMY, Martin BERTSCHINGER, Pierre MORETTI
  • EXPRESSION CASSETTE
    Publication number: 20200087679
    Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.
    Type: Application
    Filed: April 29, 2019
    Publication date: March 19, 2020
    Inventors: Christel AEBISCHER-GUMY, Martin BERTSCHINGER, Daniel LUESCHER, Pierre MORETTI
  • EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES
    Publication number: 20190056396
    Abstract: The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated directly to the amount of soluble polypeptide expressed. In the case of bispecific antibodies, cell membrane expression of heterodimer and homodimer products can be correlated directly to the soluble expression of these products, thereby aiding selection of a desired producer clone.
    Type: Application
    Filed: July 24, 2018
    Publication date: February 21, 2019
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Christel AEBISCHER-GUMY, Pierre MORETTI, Martin BERTSCHINGER
  • EXPRESSION CASSETTE
    Publication number: 20180163225
    Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.
    Type: Application
    Filed: July 18, 2017
    Publication date: June 14, 2018
    Inventors: Christel AEBISCHER-GUMY, Martin BERTSCHINGER, Daniel LUESCHER, Pierre MORETTI
  • EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES
    Publication number: 20170350886
    Abstract: The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated directly to the amount of soluble polypeptide expressed. In the case of bispecific antibodies, cell membrane expression of heterodimer and homodimer products can be correlated directly to the soluble expression of these products, thereby aiding selection of a desired producer clone.
    Type: Application
    Filed: March 2, 2015
    Publication date: December 7, 2017
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Christel AEBISCHER-GUMY, Pierre MORETTI, Martin BERTSCHINGER
  • Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic Cells
    Publication number: 20170253671
    Abstract: The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 7, 2017
    Inventors: Christel AEBISCHER-GUMY, Martin Bertschinger, Pierre Moretti
  • EXPRESSION CONSTRUCTS AND METHODS FOR EXPRESSING POLYPEPTIDES IN EUKARYOTIC CELLS
    Publication number: 20150056655
    Abstract: The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 26, 2015
    Inventors: Christel AEBISCHER-GUMY, Martin Bertschinger, Pierre Moretti
  • HUMANIZED ANTIBODIES THAT BIND TO CD19 AND THEIR USES
    Publication number: 20140286934
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 25, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Humanized antibodies that bind to CD19 and their uses
    Patent number: 8679492
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 25, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Expression Cassette
    Publication number: 20130344604
    Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.
    Type: Application
    Filed: December 5, 2012
    Publication date: December 26, 2013
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Christel Aebischer-Gumy, Martin Bertschinger, Daniel Luescher, Pierre Moretti
  • Humanized antibodies specific for von Willebrand factor
    Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • Humanized antibodies that bind to CD19 and their uses
    Publication number: 20100215651
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: STANISLAS BLEIN, DARKO SKEGRO, CHRISTOPHE DEBONNEVILLE, MARTIN BERTSCHINGER
  • HUMANIZED ANTIBODIES SPECIFIC FOR VON WILLEBRAND FACTOR
    Publication number: 20090232804
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Application
    Filed: January 23, 2009
    Publication date: September 17, 2009
    Applicant: GLENMARK PHARMACEUTICALS, S.A.,
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger